-
Signature
-
/s/ Matthew Ronsheim
-
Stock symbol
-
INVA
-
Transactions as of
-
May 20, 2024
-
Transactions value $
-
-$4,323
-
Form type
-
4
-
Date filed
-
5/21/2024, 08:15 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
INVA |
Common Stock |
Tax liability |
-$4.32K |
-268 |
-0.66% |
$16.13 |
40.5K |
May 20, 2024 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
Dr. Ronsheim is President of Innoviva Specialty Therapeutics, Inc. which is a wholly owned subsidiary of Innoviva Specialty Therapeutics Holdings, LLC, which is a wholly owned subsidiary of Innoviva, Inc.